Evidence mapPaperPMID 42196321Full record

ReviewInternational journal of molecular sciences2026

Natural Molecules for Brain Health and Resilience.

Vasiliki Venetsanaki, Eleni C Pardali, Christos Cholevas, Maria G Grammatikopoulou, Dimitrios G Goulis, Theoharis C Theoharides

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vasiliki VenetsanakiUnit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.ORCID 0000-0002-6532-7181
Eleni C PardaliImmunonutrition Unit, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, GR-41223 Larissa, Greece.ORCID 0000-0002-7864-5349
Christos CholevasDepartment of Clinical Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.ORCID 0000-0002-1517-8691
Maria G GrammatikopoulouImmunonutrition Unit, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, GR-41223 Larissa, Greece.ORCID 0000-0003-4167-6595
Dimitrios G GoulisUnit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.ORCID 0000-0002-5005-1995
Theoharis C TheoharidesInstitute for Neuro-Immune Medicine, Nova Southeastern University, Clearwater, FL 33759, USA.ORCID 0000-0002-1598-460X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global rise in cognitive decline and neurodegenerative disorders has intensified the search for safe and accessible strategies to support brain health. In recent years, nutraceuticals have gained considerable attention as potential modulators of neurological function due to their antioxidant, anti-inflammatory, and neuroprotective properties. Increasing evidence suggests that oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired neurovascular integrity play central roles in the pathogenesis of several neurodegenerative diseases, namely Alzheimer's, Parkinson's disease and autism spectrum disorder, among others. This narrative review provides an integrated overview of selected nutraceuticals with potential relevance to brain-related disorders, including biotin, folinic acid, flavonoids (apigenin, diosmin, luteolin, naringin, pycnogenol, and quercetin), huperzine A, Lion's mane, olive oil polyphenols, oleuropein and palmitoylethanolamide. Rather than presenting a purely descriptive summary, we considered both mechanistic and clinical evidence, highlighting differences in the strength, consistency, and quality of available data across compounds. Among the reviewed compounds, huperzine A, specific flavonoids-particularly luteolin-and olive oil polyphenols demonstrated relatively stronger and more consistent support across experimental models and emerging clinical studies, mainly through modulation of cholinergic signaling, neuroinflammatory pathways, and oxidative stress responses. In contrast, evidence for other agents remains limited, heterogeneous, or primarily at the preclinical level. Overall, this review aims to provide a clearer and more structured synthesis of the current literature on neuronutrition, identifying compounds with the most promising profiles while outlining key limitations and research gaps that need to be addressed to better define their role in brain health.

Indexed as

Biological ProductsBrainDietary SupplementsNeurodegenerative DiseasesNeuroprotective AgentsAnimalsAntioxidantsFlavonoidsHumansOxidative StressAntioxidantsBiological ProductsFlavonoidsNeuroprotective Agentsbiotinbraindietary supplementsflavonoidsfolic acidHericium erinaceushuperzine Ahydroxytyrosolluteolinneuronutritionoleuropeinpalmitoylethanolamide

Identifiers

PMID42196321
PMCPMC13207114

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.